Axela Biosensors and Abnova to Co-Develop Biomarker Panels

Axela Biosensors, Inc. and Abnova Corporation have announced the signing of a collaborative agreement to co-develop reagents and biomarker panels for use on Axela's dotLab System.

The dotLab System is designed to accelerate the analysis, validation and commercialization of protein biomarkers by providing real-time protein detection.
 
Abnova will optimize a series of monoclonal antibodies for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab Sensors.

Researchers will be able to combine these monoclonal antibodies with their own reagents to create custom panels for multiplexed biomarker detection. 
 
"These products will target a significant bottleneck in biomarker validation," said Dr. Wilber Huang, President of Abnova.

"Our proven ability to generate highly specific antibodies on an industrial scale combined with the unprecedented levels of sensitivity and quantitation of the dotLab System will significantly improve and accelerate the ability of pharmaceutical and translational medicine researchers to validate medically important biomarkers."
 
"We are very pleased to be collaborating with the world’s largest monoclonal antibody manufacturer to develop these biomarker panels," added Rocky Ganske, President and CEO of Axela Biosensors. 

"This is yet another step in Axela’s continued contribution to the translation of biomarker discoveries into medical and commercially valuable assays."

"Abnova’s competence in rapid production of high quality antibodies, combined with the capabilities of Axela’s dotLab System, will accelerate the entire immunoassay development process."
 
Analysis is carried out on dotLab Sensors, which employ Axela’s core Diffractive Optics Technology (dot™) in a small, disposable consumable.